BofA upgraded Regeneron (REGN) to Buy from Underperform with a price target of $860, up from $627.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Sanofi and Regeneron Expand Dupilumab’s Real-World Footprint in Chronic Urticaria
- Regeneron Advances Phase 3 Antibody Trial in Birch Pollen Eye Allergy: What Investors Should Know
- Regeneron, Sanofi get marketing authorization for Dupixent from MHLW in Japan
- Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06
- Regeneron Initiates Promising Phase 2 Study on Diabetic Kidney Disease